Get the Stockscreener App
41.50
3.31%
1.33
Pre-market:
41.87
0.37
+0.89%
Vericel Corp stock is traded at $41.50, with a volume of 413.45K.
It is up +3.31% in the last 24 hours and down -5.29% over the past month.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
See More
Previous Close:
$40.17
Open:
$40.28
24h Volume:
413.45K
Relative Volume:
0.82
Market Cap:
$2.30B
Revenue:
$226.84M
Net Income/Loss:
$3.55M
P/E Ratio:
592.86
EPS:
0.07
Net Cash Flow:
$-12.02M
1W Performance:
+0.10%
1M Performance:
-5.29%
6M Performance:
-30.29%
1Y Performance:
-9.88%
1-Day Range:
$39.70
$41.57
1-Week Range:
$39.38
$41.80
52-Week Range:
$37.39
$63.00
Vericel Corp Stock (VCEL) Company Profile
Name
Vericel Corp
Sector
Industry
Phone
(734) 930-5555
Address
64 SIDNEY ST., CAMBRIDGE, MA
Compare VCEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCEL
Vericel Corp
|
41.50 | 2.30B | 226.84M | 3.55M | -12.02M | 0.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.96 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.19 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.69 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vericel Corp Stock (VCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Initiated | Canaccord Genuity | Buy |
| Jun-20-24 | Initiated | TD Cowen | Buy |
| Jan-25-24 | Upgrade | Truist | Hold → Buy |
| Aug-08-23 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-09-22 | Downgrade | Truist | Buy → Hold |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Jan-11-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Initiated | Stephens | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Oct-09-19 | Initiated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Needham | Buy → Hold |
| Aug-08-18 | Reiterated | Needham | Buy |
| Jul-16-18 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-04-18 | Initiated | Leerink Partners | Outperform |
| Mar-06-18 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-06-18 | Reiterated | Needham | Buy |
| Mar-05-18 | Reiterated | BTIG Research | Buy |
| Jun-21-17 | Initiated | BTIG Research | Buy |
| Mar-13-17 | Reiterated | Needham | Buy |
| Dec-22-16 | Initiated | Piper Jaffray | Overweight |
| Nov-09-16 | Reiterated | Needham | Buy |
| Apr-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-11-16 | Upgrade | Needham | Hold → Buy |
View All
Vericel Corp Stock (VCEL) Latest News
Vericel at 2025 Truist Securities MedTech Conference: Growth Strategies Unveiled - Investing.com India
Vericel (NASDAQ:VCEL) Given “Overweight” Rating at Stephens - Defense World
Vericel (VCEL): Analyst Reiterates Overweight Rating with Stable Price Target | VCEL Stock News - GuruFocus
Handelsbanken Fonder AB Has $914,000 Holdings in Vericel Co. (NASDAQ:VCEL) - Defense World
Vericel Co. (NASDAQ:VCEL) Shares Sold by Rhumbline Advisers - Defense World
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025 - Yahoo Finance
GAMMA Investing LLC Acquires 127,028 Shares of Vericel Co. (NASDAQ:VCEL) - Defense World
Vericel Co. (NASDAQ:VCEL) Given Average Recommendation of “Buy” by Analysts - Defense World
3,924 Shares in Vericel Co. (NASDAQ:VCEL) Bought by Mackenzie Financial Corp - Defense World
Canaccord Genuity reiterates Buy rating on Vericel stock with $61 target - Investing.com
Bank of America Corp DE Sells 1,579 Shares of Vericel Co. (NASDAQ:VCEL) - Defense World
Vericel’s (VCEL) Overweight Rating Reiterated at Stephens - Defense World
What Analysts Are Saying About Vericel Stock - Benzinga
Vericel (VCEL) Maintains Overweight Rating by Stephens & Co. | V - GuruFocus
Vericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AG - Defense World
Vericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial Markets - Defense World
Truist maintains Buy on Vericel shares with $52 target By Investing.com - Investing.com India
Truist maintains Buy on Vericel shares with $52 target - Investing.com
VCEL to Be Featured in Upcoming Investor Meetings | VCEL Stock N - GuruFocus
Brokerages Set Vericel Co. (NASDAQ:VCEL) Price Target at $60.86 - Defense World
Vericel at BofA Securities Conference: Growth and Innovation in Healthcare By Investing.com - Investing.com India
Vericel at BofA Securities Conference: Growth and Innovation in Healthcare - Investing.com Australia
Transcript : Vericel Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 09 - marketscreener.com
VCEL: Upcoming Meeting and Market Insights | VCEL Stock News - GuruFocus
First Trust Advisors LP Lowers Stock Holdings in Vericel Co. (NASDAQ:VCEL) - Defense World
Vericel Co. (NASDAQ:VCEL) Shares Sold by Tower Research Capital LLC TRC - Defense World
Vericel Corporation (NASDAQ:VCEL) Q1 2025 Earnings Call Transcript - Insider Monkey
Vericel (VCEL) Maintains Buy Rating Despite Target Price Adjustm - GuruFocus
Vericel (VCEL) Maintains Buy Rating Despite Target Price Adjustment | VCEL Stock News - GuruFocus
Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... - Yahoo Finance
Vericel Corp Ord earnings missed by $0.10, revenue fell short of estimates - Investing.com India
Decoding Vericel Corp (VCEL): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Vericel Corp Q1 2025 sees revenue growth, stock steady - Investing.com India
Vericel Q1 2025 slides: record revenue offset by widening losses, raises guidance - Investing.com South Africa
Vericel Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Vericel (VCEL) Reports Slightly Lower Than Expected Q1 Revenue | VCEL Stock News - GuruFocus
Vericel's Q1 Loss Widens, Revenue Rises; 2025 Revenue Growth Outlook Reiterated - marketscreener.com
VCEL Updates Revenue and Profitability Outlook for 2023 | VCEL Stock News - GuruFocus
Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Vericel Corp SEC 10-Q Report - TradingView
Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling - Insider Monkey
Vericel Corp Reports Q1 2025 Earnings: EPS of -$0.23 Misses Estimates, Revenue of $52.6M Below Expectations - GuruFocus
Vericel Corporation Q1 2025 Financial Results - TradingView
Earnings Flash (VCEL) VERICEL CORPORATION Reports Q1 Revenue $52.6M, vs. FactSet Est of $53.8M - marketscreener.com
Hsbc Holdings PLC Invests $405,000 in Vericel Co. (NASDAQ:VCEL) - The AM Reporter
Earnings To Watch: Vericel Corp (VCEL) Reports Q1 2025 Result - GuruFocus
Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 - Barchart.com
Vericel’s 36% drop confirms InvestingPro’s January overvaluation warning By Investing.com - Investing.com
Vericel shareholders approve key incentive plans - Investing.com
Financial Health Report: Vericel Corp (VCEL)’s Ratios Tell a Tale - DWinneX
VCEL underperforms with a -0.26 decrease in share price - uspostnews.com
Vericel Corp Stock (VCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vericel Corp Stock (VCEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hopper Jonathan Mark | Chief Medical Officer |
Jun 02 '25 |
Sale |
40.09 |
10,000 |
400,900 |
66,237 |
1.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):